%0 Journal Article
%T Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review.
%A Liu Y
%A Li J
%A Zhu HJ
%J Expert Opin Drug Metab Toxicol
%V 20
%N 5
%D 2024 May 6
%M 38706437
%F 4.936
%R 10.1080/17425255.2024.2348491
%X <B>UNASSIGNED: </B>Carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) are among the most abundant hydrolases in humans, catalyzing the metabolism of numerous clinically important medications, such as methylphenidate and clopidogrel. The large interindividual variability in the expression and activity of CES1 and CES2 affects the pharmacokinetics (PK) and pharmacodynamics (PD) of substrate drugs.<BR><B>UNASSIGNED: </B>This review provides an up-to-date overview of CES expression and activity regulations and examines their impact on the PK and PD of CES substrate drugs. The literature search was conducted on PubMed from inception to January 2024.<BR><B>UNASSIGNED: </B>Current research revealed modest associations of CES genetic polymorphisms with drug exposure and response. Beyond genomic polymorphisms, transcriptional and posttranslational regulations can also significantly affect CES expression and activity and consequently alter PK and PD. Recent advances in plasma biomarkers of drug-metabolizing enzymes encourage the research of plasma protein and metabolite biomarkers for CES1 and CES2, which could lead to the establishment of precision pharmacotherapy regimens for drugs metabolized by CESs. Moreover, our understanding of tissue-specific expression and substrate selectivity of CES1 and CES2 has shed light on improving the design of CES1- and CES2-activated prodrugs.